{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T05:05:57Z","timestamp":1779426357889,"version":"3.53.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100008750","name":"Shanghai Hospital Development Center","doi-asserted-by":"crossref","award":["No. SHDC12023103"],"award-info":[{"award-number":["No. SHDC12023103"]}],"id":[{"id":"10.13039\/501100008750","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Shanghai Scientific and Technological Innovation Program","award":["No. 21XD1431300"],"award-info":[{"award-number":["No. 21XD1431300"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s00259-026-07811-8","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T06:03:45Z","timestamp":1770962625000},"page":"4405-4413","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical performance of [99mTc]Tc-HYNIC-PSMA-XL-2 SPECT\/CT in prostate cancer: paired head-to-head comparisons with [99mTc]Tc-MDP and PSMA PET\/CT"],"prefix":"10.1007","volume":"53","author":[{"given":"Linjie","family":"Bian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoli","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,13]]},"reference":[{"key":"7811_CR1","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s40336-016-0196-5","volume":"4","author":"GJR Cook","year":"2016","unstructured":"Cook GJR, Azad G, Padhani AR. Bone imaging in prostate cancer: the evolving roles of nuclear medicine and radiology. Clin Translational Imaging. 2016;4:439\u201347. https:\/\/doi.org\/10.1007\/s40336-016-0196-5.","journal-title":"Clin Translational Imaging"},{"key":"7811_CR2","doi-asserted-by":"publisher","unstructured":"Baldessari C, Pipitone S, Molinaro E, Cerma K, Fanelli M, Nasso C, et al. Bone metastases and health in prostate cancer: from pathophysiology to clinical implications. Cancers (Basel). 2023;15. https:\/\/doi.org\/10.3390\/cancers15051518.","DOI":"10.3390\/cancers15051518"},{"key":"7811_CR3","doi-asserted-by":"publisher","first-page":"217310","DOI":"10.1016\/j.canlet.2024.217310","volume":"606","author":"GK Guruvayurappan","year":"2024","unstructured":"Guruvayurappan GK, Frankenbach-D\u00e9sor T, Laubach M, Klein A, von Bergwelt-Baildon M, Cusan M, et al. Clinical challenges in prostate cancer management: metastatic bone-tropism and the role of Circulating tumor cells. Cancer Lett. 2024;606:217310. https:\/\/doi.org\/10.1016\/j.canlet.2024.217310.","journal-title":"Cancer Lett"},{"key":"7811_CR4","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/S0140-6736(21)00950-8","volume":"398","author":"S Sandhu","year":"2021","unstructured":"Sandhu S, Moore CM, Chiong E, Beltran H, Bristow RG, Williams SG. Prostate cancer. Lancet. 2021;398:1075\u201390. https:\/\/doi.org\/10.1016\/S0140-6736(21)00950-8.","journal-title":"Lancet"},{"key":"7811_CR5","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1053\/j.semnuclmed.2023.07.004","volume":"54","author":"N Mohseninia","year":"2024","unstructured":"Mohseninia N, Zamani-Siahkali N, Harsini S, Divband G, Pirich C, Beheshti M. Bone metastasis in prostate cancer: bone scan versus PET imaging. Semin Nucl Med. 2024;54:97\u2013118. https:\/\/doi.org\/10.1053\/j.semnuclmed.2023.07.004.","journal-title":"Semin Nucl Med"},{"key":"7811_CR6","doi-asserted-by":"publisher","first-page":"1320574","DOI":"10.3389\/fmed.2023.1320574","volume":"10","author":"E Ouvrard","year":"2023","unstructured":"Ouvrard E, Kaseb A, Poterszman N, Porot C, Somme F, Imperiale A. Nuclear medicine imaging for bone metastases assessment: what else besides bone scintigraphy in the era of personalized medicine? Front Med (Lausanne). 2023;10:1320574. https:\/\/doi.org\/10.3389\/fmed.2023.1320574.","journal-title":"Front Med (Lausanne)"},{"key":"7811_CR7","doi-asserted-by":"publisher","first-page":"74","DOI":"10.4103\/ijnm.ijnm_104_21","volume":"37","author":"A Meena","year":"2022","unstructured":"Meena A, Veerwal H, Dhingra VK, Dhingra M. Role of 99mTc-Methylene diphosphonate bone scintigraphy in the evaluation of the viability and the incorporation of the bone allograft used in orthopedic reconstruction. Indian J Nucl Med. 2022;37:74\u20137. https:\/\/doi.org\/10.4103\/ijnm.ijnm_104_21.","journal-title":"Indian J Nucl Med"},{"key":"7811_CR8","doi-asserted-by":"publisher","unstructured":"Keegan NM, Bodei L, Morris MJ. Seek and find: current prospective evidence for prostate-specific membrane antigen imaging to detect recurrent prostate cancer. Eur Urol Focus. 2021;7. https:\/\/doi.org\/10.1016\/j.euf.2021.03.012. :267\u2009\u2013\u200978.","DOI":"10.1016\/j.euf.2021.03.012"},{"key":"7811_CR9","doi-asserted-by":"publisher","first-page":"3130","DOI":"10.21037\/tau-20-1047","volume":"10","author":"I de Kouchkovsky","year":"2021","unstructured":"de Kouchkovsky I, Aggarwal R, Hope TA. Prostate-specific membrane antigen (PSMA)-based imaging in localized and advanced prostate cancer: a narrative review. Transl Androl Urol. 2021;10:3130\u201343. https:\/\/doi.org\/10.21037\/tau-20-1047.","journal-title":"Transl Androl Urol"},{"key":"7811_CR10","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1007\/s00259-022-06089-w","volume":"50","author":"WP Fendler","year":"2023","unstructured":"Fendler WP, Eiber M, Beheshti M, Bomanji J, Calais J, Ceci F, et al. PSMA PET\/CT: joint EANM procedure guideline\/SNMMI procedure standard for prostate cancer imaging 2.0. Eur J Nucl Med Mol Imaging. 2023;50:1466\u201386. https:\/\/doi.org\/10.1007\/s00259-022-06089-w.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7811_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11604-024-01646-9","volume":"43","author":"T Otani","year":"2025","unstructured":"Otani T, Nakamoto R, Umeoka S, Nakamoto Y. PSMA PET\/CT imaging and its application to prostate cancer treatment. Japanese J Radiol. 2025;43:1\u201312. https:\/\/doi.org\/10.1007\/s11604-024-01646-9.","journal-title":"Japanese J Radiol"},{"key":"7811_CR12","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1007\/s12149-022-01804-x","volume":"37","author":"H Yang","year":"2023","unstructured":"Yang H, Gao Z, Xu X, Liu C, Hu S, Zhang J, et al. Dosimetry Estimation and preliminary clinical application of [(99m)Tc]Tc-HYNIC-PSMA-XL-2 in prostate cancer. Ann Nucl Med. 2023;37:60\u20139. https:\/\/doi.org\/10.1007\/s12149-022-01804-x.","journal-title":"Ann Nucl Med"},{"key":"7811_CR13","volume-title":"Shanghai Shiya pharmaceutical technology Co L","author":"S Song","year":"2023","unstructured":"Song S, Xu X, Liu C. A PSMA binding agent and use thereof. Shanghai Shiya pharmaceutical technology Co L. editor. China: China National Intellectual Property Administration (CNIPA); 2023."},{"key":"7811_CR14","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1001\/jamaoncol.2019.0096","volume":"5","author":"WP Fendler","year":"2019","unstructured":"Fendler WP, Calais J, Eiber M, Flavell RR, Mishoe A, Feng FY, et al. Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: A prospective Single-Arm clinical trial. JAMA Oncol. 2019;5:856\u201363. https:\/\/doi.org\/10.1001\/jamaoncol.2019.0096.","journal-title":"JAMA Oncol"},{"key":"7811_CR15","doi-asserted-by":"publisher","first-page":"e012799","DOI":"10.1136\/bmjopen-2016-012799","volume":"6","author":"JF Cohen","year":"2016","unstructured":"Cohen JF, Korevaar DA, Altman DG, Bruns DE, Gatsonis CA, Hooft L, et al. STARD 2015 guidelines for reporting diagnostic accuracy studies: explanation and elaboration. BMJ Open. 2016;6:e012799. https:\/\/doi.org\/10.1136\/bmjopen-2016-012799.","journal-title":"BMJ Open"},{"key":"7811_CR16","doi-asserted-by":"publisher","first-page":"15993","DOI":"10.1038\/s41598-022-20280-x","volume":"12","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Lin Z, Li T, Wei Y, Yu M, Ye L, et al. Head-to-head comparison of (99m)Tc-PSMA and (99m)Tc-MDP SPECT\/CT in diagnosing prostate cancer bone metastasis: a prospective, comparative imaging trial. Sci Rep. 2022;12:15993. https:\/\/doi.org\/10.1038\/s41598-022-20280-x.","journal-title":"Sci Rep"},{"key":"7811_CR17","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1097\/mnm.0000000000001733","volume":"44","author":"T Ghaedian","year":"2023","unstructured":"Ghaedian T, Abdinejad M, Nasrollahi H, Ghaedian M, Firuzyar T. Comparing the role of 99m Tc-HYNIC-PSMA-11 and 99m Tc-MDP scintigraphy for the initial staging of intermediate to high-risk prostate cancer. Nucl Med Commun. 2023;44:864\u20139. https:\/\/doi.org\/10.1097\/mnm.0000000000001733.","journal-title":"Nucl Med Commun"},{"key":"7811_CR18","doi-asserted-by":"publisher","first-page":"6082","DOI":"10.7150\/thno.44584","volume":"10","author":"DA Ferraro","year":"2020","unstructured":"Ferraro DA, R\u00fcschoff JH, Muehlematter UJ, Kranzb\u00fchler B, M\u00fcller J, Messerli M, et al. Immunohistochemical PSMA expression patterns of primary prostate cancer tissue are associated with the detection rate of biochemical recurrence with (68)Ga-PSMA-11-PET. Theranostics. 2020;10:6082\u201394. https:\/\/doi.org\/10.7150\/thno.44584.","journal-title":"Theranostics"},{"key":"7811_CR19","doi-asserted-by":"publisher","first-page":"15013","DOI":"10.1038\/boneres.2015.13","volume":"3","author":"ZA Zhong","year":"2015","unstructured":"Zhong ZA, Peck A, Li S, VanOss J, Snider J, Droscha CJ, et al. (99m)TC-Methylene diphosphonate uptake at injury site correlates with osteoblast differentiation and mineralization during bone healing in mice. Bone Res. 2015;3:15013. https:\/\/doi.org\/10.1038\/boneres.2015.13.","journal-title":"Bone Res"},{"key":"7811_CR20","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s00296-011-2141-2","volume":"32","author":"E Eriksen","year":"2011","unstructured":"Eriksen E, Ringe J. Bone marrow lesions: A universal bone response to injury? Rheumatol Int. 2011;32:575\u201384. https:\/\/doi.org\/10.1007\/s00296-011-2141-2.","journal-title":"Rheumatol Int"},{"key":"7811_CR21","doi-asserted-by":"publisher","first-page":"4483","DOI":"10.1007\/s00259-021-05424-x","volume":"48","author":"H Gr\u00fcnig","year":"2021","unstructured":"Gr\u00fcnig H, Maurer A, Thali Y, Kovacs Z, Strobel K, Burger IA, et al. Focal unspecific bone uptake on [(18)F]-PSMA-1007 PET: a multicenter retrospective evaluation of the distribution, frequency, and quantitative parameters of a potential pitfall in prostate cancer imaging. Eur J Nucl Med Mol Imaging. 2021;48:4483\u201394. https:\/\/doi.org\/10.1007\/s00259-021-05424-x.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7811_CR22","doi-asserted-by":"publisher","first-page":"738","DOI":"10.2967\/jnumed.118.215434","volume":"64","author":"R Seifert","year":"2023","unstructured":"Seifert R, Telli T, Opitz M, Barbato F, Berliner C, Nader M, et al. Unspecific (18)F-PSMA-1007 bone uptake evaluated through PSMA-11 PET, bone Scanning, and MRI triple validation in patients with biochemical recurrence of prostate cancer. J Nucl Med. 2023;64:738\u201343. https:\/\/doi.org\/10.2967\/jnumed.118.215434.","journal-title":"J Nucl Med"},{"key":"7811_CR23","doi-asserted-by":"publisher","first-page":"3753","DOI":"10.1007\/s00259-024-06797-5","volume":"51","author":"A Rizzo","year":"2024","unstructured":"Rizzo A, Morbelli S, Albano D, Fornarini G, Cioffi M, Laudicella R, et al. The homunculus of unspecific bone uptakes associated with PSMA-targeted tracers: a systematic review-based definition. Eur J Nucl Med Mol Imaging. 2024;51:3753\u201364. https:\/\/doi.org\/10.1007\/s00259-024-06797-5.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7811_CR24","doi-asserted-by":"publisher","first-page":"e68","DOI":"10.1097\/rlu.0000000000003410","volume":"46","author":"B Fallahi","year":"2021","unstructured":"Fallahi B, Khademi N, Karamzade-Ziarati N, Fard-Esfahani A, Emami-Ardekani A, Farzanefar S, et al. 99mTc-PSMA SPECT\/CT versus 68Ga-PSMA PET\/CT in the evaluation of metastatic prostate cancer. Clin Nucl Med. 2021;46:e68\u201374. https:\/\/doi.org\/10.1097\/rlu.0000000000003410.","journal-title":"Clin Nucl Med"},{"key":"7811_CR25","doi-asserted-by":"publisher","first-page":"104556","DOI":"10.1016\/j.critrevonc.2024.104556","volume":"205","author":"JR Puik","year":"2025","unstructured":"Puik JR, Le C, Kazemier G, Oprea-Lager DE, Swijnenburg R-J, Giovannetti E, et al. Prostate-specific membrane antigen as target for vasculature-directed therapeutic strategies in solid tumors. Crit Rev Oncol\/Hematol. 2025;205:104556. https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104556.","journal-title":"Crit Rev Oncol\/Hematol"},{"key":"7811_CR26","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s40658-025-00724-9","volume":"12","author":"Z Cheng","year":"2025","unstructured":"Cheng Z, Chen P, Yan J. A review of state-of-the-art resolution improvement techniques in SPECT imaging. EJNMMI Phys. 2025;12:9. https:\/\/doi.org\/10.1186\/s40658-025-00724-9.","journal-title":"EJNMMI Phys"},{"key":"7811_CR27","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1097\/MNM.0b013e3282f3a515","volume":"29","author":"A Rahmim","year":"2008","unstructured":"Rahmim A, Zaidi H. PET versus SPECT: strengths, limitations and challenges. Nucl Med Commun. 2008;29:193\u2013207. https:\/\/doi.org\/10.1097\/MNM.0b013e3282f3a515.","journal-title":"Nucl Med Commun"},{"key":"7811_CR28","doi-asserted-by":"publisher","first-page":"e250019","DOI":"10.1148\/rycan.250019","volume":"7","author":"HK Hussain","year":"2025","unstructured":"Hussain HK, Rajeev R, DeStigter KK, Gulani V. Global cancer imaging access: addressing barriers and Harnessing innovations. Radiol Imaging Cancer. 2025;7:e250019. https:\/\/doi.org\/10.1148\/rycan.250019.","journal-title":"Radiol Imaging Cancer"},{"key":"7811_CR29","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1053\/j.semnuclmed.2025.07.005","volume":"55","author":"A Al-Ibraheem","year":"2025","unstructured":"Al-Ibraheem A, Brink A, Lee ST, De Los Reyes A, Paez D, Craviolatti PS, et al. Implementation of radiotheranostics: Challenges, Barriers, and IAEA-Driven strategies for sustainable access. Semin Nucl Med. 2025;55:1032\u201344. https:\/\/doi.org\/10.1053\/j.semnuclmed.2025.07.005.","journal-title":"Semin Nucl Med"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07811-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-07811-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07811-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T04:12:06Z","timestamp":1779423126000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-026-07811-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,13]]},"references-count":29,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["7811"],"URL":"https:\/\/doi.org\/10.1007\/s00259-026-07811-8","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,13]]},"assertion":[{"value":"10 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This single-center retrospective study was approved by the Ethics Committee of Fudan University Shanghai Cancer Center (No. 1612167-18) and conducted in accordance with the Declaration of Helsinki. Owing to the retrospective design and use of de-identified data, the requirement for written informed consent was waived.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable (the study does not include any individual person\u2019s identifiable data, images, or videos).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}